Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 13 of 13 for “"High Throughput Drug Screening"”.

  1. Expanding the Capabilities of Paper Spray Mass Spectrometry: High-Throughput Drug Screening and On-Paper Electrokinetic Stacking

    … the application of PS-MS in fields requiring high sensitivity in analysis of complex biological matrices. This dissertation explores approaches to enhance the capabilities and applications of PS-MS, with a particular focus on overcoming sensitivity limitations. Chapter 2 demonstrates the …

    iupui Repository record for Expanding the Capabilities of Paper Spray Mass Spectrometry: High-Throughput Drug Screening and On-Paper Electrokinetic Stacking (opens in a new tab)

  2. A Variational Lower Bound to Mitigate Batch Effect in Molecular Representations

    High-throughput drug screening – using cell imaging or gene expression measurements as readouts of drug effect – is a critical tool in biotechnology to assess and understand the relationship between the chemical structure and biological activity of a drug. Since large-scale screens have to be …

    mit Repository record for A Variational Lower Bound to Mitigate Batch Effect in Molecular Representations (opens in a new tab)

  3. In vivo identification of drug therapeutics for nemaline myopathy

    … study employs the DiscoveryProbeTM FDA-approved drug library to perform a small molecule high-throughput drug screen as a strategy for developing therapies for Nemaline Myopathy (NM). Nemaline myopathy is a rare congenital neuromuscular disorder characterized by muscle weakness and the …

    bu Repository record for In vivo identification of drug therapeutics for nemaline myopathy (opens in a new tab)

  4. A two-pronged approach towards the development of novel therapeutics for advanced endometrial cancer

    … culture model that is compatible with existing high throughput drug screening methodologies. This system incorporates three layers: an acellular cushion layer; an encapsulated cancer cell layer for growth in 3D; and a collagen-containing layer that supports the growth of stromal cells on top of …

    rice Repository record for A two-pronged approach towards the development of novel therapeutics for advanced endometrial cancer (opens in a new tab)

  5. Identification and functional characterisation of gene fusions in human cancer cell lines

    … oncogenic phenotypes and their relevance in drug response. In this study, I combine RNA sequencing, CRISPR/Cas9 screens and high-throughput drug sensitivity data in a panel of 1,011 human cancer cell lines across 42 tissue types to examine the occurrence and functional relevance of gene …

    cambridge Repository record for Identification and functional characterisation of gene fusions in human cancer cell lines (opens in a new tab)

  6. Human Embryonic stem cell-derived A9 dopaminergic neurons as a model and therapy for Parkinson's disease

    … cell source for both cell therapies and drug screening platforms for PD. A hallmark pathology of PD involves the atypical aggregation of alpha synuclein and subsequent formation of Lewy pathology. The trigger for *de novo* alpha synuclein aggregation is as of yet unknown, however, the A9 …

    cambridge Repository record for Human Embryonic stem cell-derived A9 dopaminergic neurons as a model and therapy for Parkinson's disease (opens in a new tab)

  7. Deconvoluting genetic variants associated with aortic disease using stem cell models

    … prognostication, and determination of cascade screening requirements. This study aimed to utilise induced pluripotent stem cell (iPSC) models of TAD to analyse genetic variants from the 100,000 Genomes Project by determining causality, disease mechanisms and identifying drug targets. We focused …

    cambridge Repository record for Deconvoluting genetic variants associated with aortic disease using stem cell models (opens in a new tab)

  8. Integrative mathematical modelling of drug responses in breast cancer PDTXs and ex vivo PDTCs

    … and experimental approaches to investigate drug responses in breast cancer, utilising patient-derived tumour xenografts (PDTXs) and ex vivo PDTX-derived tumour cells (PDTCs). A robust biobank of over 100 PDTXs, encompassing diverse breast cancer subtypes, was expanded and genomically …

    cambridge Repository record for Integrative mathematical modelling of drug responses in breast cancer PDTXs and ex vivo PDTCs (opens in a new tab)

  9. Mechanisms driving the expansion and progression of splicing factor-mutant clonal haematopoiesis

    … of CH, particularly in the elderly, and confer a high risk of progression to haematological malignancy. Despite over a decade of research into CH, we still lack an understanding of the mechanisms through which splicing factor mutations drive CH and how cells harbouring these mutations can be …

    cambridge Repository record for Mechanisms driving the expansion and progression of splicing factor-mutant clonal haematopoiesis (opens in a new tab)

  10. Investigating the Genomics and Heterogeneity of Childhood Non-Hodgkin Lymphoma

    … lymphoblastic lymphomas. Most childhood NHL is high-grade and generally responds well to high-intensity chemotherapy. Unfortunately, many patients who relapse have a dismal prognosis, with long-term survival less than 30% for relapsed BL patients in particular. Furthermore, the side effects of …

    cambridge Repository record for Investigating the Genomics and Heterogeneity of Childhood Non-Hodgkin Lymphoma (opens in a new tab)

  11. Discovery of Dihydroartemisinin and Dasatinib Drug Combination to Cure Pooroutcome BCR-ABL+ Acute Lymphoblastic Leukemia

    … and chronic myelogenous leukemia (CML). Food and Drug Administration (FDA)- approved BCR-ABL-specific kinase inhibitors (BCR-ABL–KIs) imatinib, dasatinib and nilotinib induce prolonged remissions in CML but poor leukemia-reduction and relapse-control in Ph+ ALL. The relative primary …

    tenn-hsc Repository record for Discovery of Dihydroartemisinin and Dasatinib Drug Combination to Cure Pooroutcome BCR-ABL+ Acute Lymphoblastic Leukemia (opens in a new tab)